Tetracosactide - Novartis

Drug Profile

Tetracosactide - Novartis

Alternative Names: Corticotropin tetracosapeptide; Cosyntropin; MNK-1411; Synacthen; Synacthen Depot; Tetracosactide hexa-acetate salt - Novartis

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Alliance Pharmaceuticals Limited; Defiante Farmaceutica; Leadiant Biosciences; Mallinckrodt plc; Novartis; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Corticosteroids; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adrenal insufficiency; Autoimmune disorders; Infantile spasms; Inflammation; Multiple sclerosis
  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 02 Aug 2018 Tetracosactide - Novartis receives Orphan Drug status for Duchenne muscular dystrophy in European Union
  • 02 Aug 2018 Mallinckrodt initiates enrolment in the phase II BRAVE trial for Duchenne muscular dystrophy (In children) in USA and Spain
  • 17 Jul 2018 Phase-II clinical trials in Duchenne muscular dystrophy (In children) in Spain and USA (SC) (NCT03400852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top